51
Views
0
CrossRef citations to date
0
Altmetric
Case Report

Weight reduction and pioglitazone ameliorate polycystic ovary syndrome after removal of a Sertoli-stromal cell tumor

, , , , , , , , & show all
Pages 607-611 | Published online: 23 Nov 2012

References

  • NovakERLongJHArrhenoblastoma of the ovaryAm J Obstet Gynecol1965921082109314337029
  • FranksSMcCarthyMIHardyKDevelopment of polycystic ovary syndrome: involvement of genetic and environmental factorsInt J Androl20062927828516390494
  • BabaTEndoTIkedaKDistinctive features of female-to-male transsexualism and prevalence of gender identity disorder in JapanJ Sex Med201181686169321477021
  • MorenoSAShyamAMorgentalerAComparison of free testosterone results by analog radioimmunoassay and calculated free testosterone in an ambulatory clinical populationJ Sex Med201071948195319732301
  • BabaTEndoTSataFThe contributions of resistin and adiponectin gene single nucleotide polymorphisms to the genetic risk for polycystic ovary syndrome in a Japanese populationGynecol Endocrinol20092549850319544118
  • LiXJYuYXLiuCQMetformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysisClin Endocrinol201174332339
  • YoungRHScullyREOvarian Sertoli Leydig cell tumors: A clinicopathological analysis of 207 casesAm J Surg Pathol198595435693911780
  • ZawadskiJKDunaifADiagnostic criteria for polycystic ovary syndrome: toward a rational approachDunaifAGivensJRHaseltineFPolycystic Ovary SyndromeBoston, MABlackwell Scientific Publications1992
  • The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop GroupRevised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndromeFertil Steril2004811925
  • AzzizRCarminaEDewaillyDAndrogen Excess SocietyPositions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guidelineJ Clin Endocrinol Metab2006914237424516940456
  • ArltWAuchusRJMillerWLThiazolidinediones but not metformin directly inhibit the steroidogenic enzymes P450c17 and 3betahydroxysteroid dehydrogenaseJ Biol Chem2001276167671677111278997
  • KempnáPHoferGMullisPEFlückCEPioglitazone inhibits androgen production in NCI-H295R cells by regulating gene expression of CYP17 and HSD3B2Mol Pharmacol20077178779817138841
  • Ortega-GonzálezCLunaSHernándezLResponses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndromeJ Clin Endocrinol Metab2005901360136515598674
  • JungheimESOdiboAOFertility treatment in women with polycystic ovary syndrome: a decision analysis of different oral ovulation induction agentsFertil Steril2010942659266420451181
  • TangTLordJMNormanRJYasminEBalenAHInsulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertilityCochrane Database Syst Rev20101CD00305320091537
  • Huber-BuchholzMMCareyDGNormanRJRestoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormoneJ Clin Endocrinol Metab1999841470147410199797
  • MoranLJHutchisonSKNormanRJTeedeHJLifestyle changes in women with polycystic ovary syndromeCochrane Database Syst Rev20117CD00750621735412